

BGB-11417 (Bcl-2 Inhibitor) Monotherapy or Combination with Zanubrutinib in CLL/SLL Patients: Preliminary Phase 1 Data

Poster # BSH23-PO154

Murali Kesavan,¹ Chan Y. Cheah,^{2,3,4} Constantine S. Tam,^{5,6} Masa Lasica,⁷ Emma Verner,^{8,9} Peter J. Browett,¹⁰ Mary Ann Anderson,^{11,12} James Hilger,¹³ Yiqian Fang,¹³ David Simpson,¹³ Stephen Opat^{6,14}

¹Department of Haematology, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals, Oxford, UK; ²Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, WA, Australia; ³Medical School, University of Western Australia, Crawley, WA, Australia; ⁴Linear Clinical Research, Nedlands, WA, Australia; ⁵Alfred Hospital, Melbourne, VIC, Australia; ⁶Monash University, Clayton, VIC, Australia; ⁷St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; ⁸Concord Repatriation General Hospital, Concord, NSW, Australia; ⁹University of Sydney, Sydney, NSW, Australia; ¹⁰Department of Haematology, Auckland City Hospital, Auckland, New Zealand; ¹¹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; ¹²Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Parkville, VIC, Australia; ¹³BeiGene (Shanghai) Co., Ltd., Shanghai, China and BeiGene USA, Inc., San Mateo, CA, USA; and ¹⁴Monash Health, Clayton, VIC, Australia

INTRODUCTION


- Bcl-2 inhibition is an established mechanism for treating B-cell malignancies such as chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)¹
- The combination of inhibitors of Bcl-2 (Bcl-2) and Bruton tyrosine kinase (BTK) has potent activity in CLL and mantle cell lymphoma (MCL)^{3,6}
- Ibrutinib with venetoclax in patients with CLL/SLL appears to be effective; however, adverse events (AEs) may limit their use, leaving an unmet need for a safe and efficacious BTK + Bcl-2i combination regimen²
- BGB-11417 has shown more potent and selective Bcl-2 inhibition and better activity against tumors with BCL2 mutations than venetoclax in vitro²
 - BGB-11417 has a 14x higher affinity for Bcl-2 than venetoclax; additionally, BGB-11417 has a relative selectivity for Bcl-xL and for BCL-w that is 6x and 9x lower, respectively, than venetoclax
- Zanubrutinib, a next-generation BTK inhibitor, has demonstrated superior efficacy and safety, especially cardiovascular, in head-to-head studies with ibrutinib^{8,9}
- Here, preliminary data are presented from a phase 1 study of BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL

METHODS

STUDY DESIGN

BGB-11417-101 (NCT04277637) is a first-in-human, phase 1, multicenter study in patients with B-cell malignancies; the study design for the CLL/SLL cohorts is shown in Figure 1

Figure 1. NCT04277637 Study Design




*For reduction in ALC, only data from patients with an ALC >5x10⁹/L at baseline were included; minimum ALC among 1 week of each dose level was used for calculation and ALC data were pooled from both monotherapy and combination therapy cohorts. †MRD was measured by ERIC flow cytometry with 10⁻⁴ sensitivity. ALC, absolute lymphocyte count; Bcl-2, B-cell lymphoma 2; BID, twice daily; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ERIC, European Research Initiative on CLL; iwCLL, International Workshop on CLL; MRD, minimal residual disease; ORR, overall response rate; QD, every day; RP2D, recommended phase 2 dose; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma; TN, treatment-naïve; ULN, upper limit of normal.

DOSE RAMP-UP

- To mitigate potential tumor lysis syndrome (TLS), all patients received either a weekly or daily dose ramp-up to the BGB-11417 target dose (Figure 2)
- TLS prophylaxis also included hydration starting 24-48 hours prior to first dose, allopurinol starting 2-3 days prior to first dose, and rasburicase as indicated


Figure 2. Example BGB-11417 Dose Ramp-up Schedules



RESULTS

- As of September 1, 2022, 79 patients with CLL/SLL received either BGB-11417 as monotherapy (n=8) or in combination with zanubrutinib (n=71; Figure 3)

Figure 3. Patient Disposition



Data cutoff date: September 1, 2022. †Patients in the zanubrutinib pretreatment phase who have not yet received BGB-11417. ††All patients were assigned to a weekly ramp-up schedule except for n=4 TN patients (320 mg dose level). CLL, chronic lymphocytic leukemia; mo, month; PD, progressive disease; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma; TN, treatment-naïve.

- The overall study population had a median age of 62 years and 79% of patients were male (Table 1)
- Del(17p) and TP53 mutation were found in 17% and 23% of patients, respectively

Table 1. Baseline Patient Demographics and Clinical Characteristics

Characteristic	BGB-11417 monotherapy (n=8)	BGB-11417 + zanubrutinib (n=71)	All patients (N=79)
Median age, (range), years	68.5 (55-84)	61.0 (35-84)	62.0 (35-84)
Sex, n (%)			
Male	6 (75.0)	56 (78.9)	62 (78.5)
Female	2 (25.0)	15 (21.1)	17 (21.5)
ECOG PS, n (%)			
0	3 (37.5)	49 (69.0)	52 (65.8)
1	5 (62.5)	21 (29.6)	26 (32.9)
2	0	1 (1.4)	1 (1.3)
Disease type, n (%)			
CLL	8 (100)	70 (99)	78 (99)
SLL	0	1 (1)	1 (1)
R/R, n (%)	8 (100)	25 (35.2)	33 (41.8)
Number of prior lines of therapy, median (range)	2 (1-3)	1 (1-2)	1 (1-3)
Time from end of most recent systemic therapy to first dose, median (range), months	0.4 (0.0-10.2)	57.0 (1.6-194.4)	45.4 (0.0-194.4)
TN, n (%)	0	46 (64.8)	46 (58.2)
Risk status, n (%)			
del(17p)	2 (25)	11 (15.5)	13 (16.5)
TP53 ^{mut}	3 (37.5)	15 (21.1)	18 (22.8)

CLL, chronic lymphocytic leukemia; del(17p), deletion in chromosome 17p; ECOG, Eastern Cooperative Oncology Group Performance Status; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma; TN, treatment-naïve; TP53^{mut}, mutation of p53.

SAFETY


- Toxicity did not seem dose dependent; only 1 DLT (febrile neutropenia) occurred among patients receiving monotherapy (80 mg) and no DLTs have been observed to date with combination therapy at any dose level (Table 2)
- No AEs leading to death or BGB-11417 discontinuation occurred in any patients
- The most common AEs are shown in Figure 4; TEAEs of interest included TLS, GI toxicity, and neutropenia
 - No clinical TLS occurred; one event of laboratory TLS occurred in a patient with high tumor burden who was receiving monotherapy
 - No TLS was observed with daily ramp-up (TN combination, 320 mg; n=3)
 - Diarrhea was mostly grade 1; 12.5% in the monotherapy cohort and 5.6% in the combination cohort had grade ≥2 diarrhea and 1 patient in the combination cohort had grade 3 diarrhea
- Granulocyte-colony stimulating factor (G-CSF) was administered to 50% of patients in the monotherapy cohort and 14.1% in the combination cohort to treat neutropenia
 - 3.8% of patients received >1 course of G-CSF to treat neutropenia

Table 2. Safety Summary

TEAE, n (%)	BGB-11417 monotherapy (n=8)	BGB-11417 + zanubrutinib (n=71)	All patients (N=79)
Any AEs	8 (100)	61 (86)	69 (87)
Grade ≥3	5 (63)	20 (28)	25 (32)
Serious AEs	2 (25)	7 (10)	9 (11)
Treated with BGB-11417	8	50	58
Leading to hold of BGB-11417	5 (62.5)	14 (28)	19 (33)
Leading to dose reduction of BGB-11417	0	1 (2)	1 (2)

AE, adverse event; TEAE, treatment-emergent adverse event.

Figure 4. Most Frequent AEs



*Includes 21 patients who were still in the zanubrutinib pretreatment phase and had not yet received BGB-11417; †Includes 46 patients who were TN. ALT, alanine aminotransferase; COVID-19, coronavirus disease of 2019; GERD, gastroesophageal reflux disease; TN, treatment-naïve; URTI, upper respiratory tract infection.

EFFICACY


- With a median follow-up of 13.4 months in the BGB-11417 monotherapy cohort and 11.1 months in the BGB-11417 combination cohort, patients with R/R CLL/SLL had an ORR of 67% and 95%, respectively (Table 3)

Table 3. ORR

Parameter	BGB-11417 monotherapy	BGB-11417 + zanubrutinib	
	R/R (n=8)	R/R (n=25)	TN (n=46)
Treated with BGB-11417	8	24	26
Efficacy-evaluable	6	20*	11*
ORR	4 (67)	19 (95)	11 (100)
CR	2 (33)	6 (30)	2 (18)
PR	2 (33)	13 (65)	9 (82)
SD	2 (33)	1 (5)	0
PD	0	0	0
Median follow-up, months (range)	13.4 (1.4-21.9)	11.1 (2.2-18.6)	3.5 (0.4-9.7)

*n=2 (R/R) and n=11 (TN) responded after zanubrutinib pretreatment but have not yet had response assessment on combination treatment; they are not included here. CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease; TN, treatment-naïve.

Figure 5. Reduction in Absolute Lymphocyte Counts



Only data from patients with an ALC >5x10⁹/L at baseline were included. Box plots represent median and 10th-90th percentiles. *Minimum ALC among 1 week of each dose level was used for calculation. N represents the number of patients who completed weekly dosing at the dose level underneath. ALC data were pooled from both monotherapy (n=7) and combination therapy (n=39) cohorts because no difference was observed. ALC, absolute lymphocyte count.

CONCLUSIONS

- BGB-11417, alone or in combination with zanubrutinib, was well tolerated in patients with TN or R/R CLL/SLL
 - Dose escalation continues to 640 mg with only 1 DLT; Grade ≥3 neutropenia and grade ≥2 diarrhea were uncommon and manageable
 - Only 1 event of laboratory TLS was seen; TLS was mitigated by the prophylactic measures and ramp-up schedule
 - The AEs observed in this trial were consistent with those observed in a BGB-11417 study in patients with NHL⁹, in which doses up to 640 mg were tested and no MTD was reached
- Promising efficacy was seen with BGB-11417 as monotherapy and in combination with zanubrutinib in both TN and R/R CLL/SLL
- Based on ALC reduction, BGB-11417 may be ~5X as potent as venetoclax by dose
- MRD data are preliminary but appear promising
- A cohort of venetoclax-treated patients with CLL/SLL is currently recruiting

REFERENCES

- Yaguchi et al. *Cell Death Dis.* 2020;11(7):694.
- Hu N, et al. *ASCO* 2020, Abstract 3077.
- Soumerai JD, et al. *Lancet Haematol.* 2021;1(10):e779-e790.
- Hilmer P, et al. *J Clin Oncol.* 2019;37(20):2722-2729.
- Jain N, et al. *N Engl J Med.* 2019;380(21):2095-2103.
- Warda W, et al. *J Clin Oncol.* 2021;39(9):953-965.
- Kater AP, et al. *NEJM Evid.* 2022;3(7):doi: 10.1056/EVIDO2200006.
- Brown JR, et al. *ASCO* 2022, Abstract CLL115.
- Tem CS, et al. *ASCO* 2022, Abstract 7521.
- Soumerai JD, et al. *ASH* 2022, Abstract 4201.
- Roberts AW, et al. *N Engl J Med.* 2016;374(8):31-322.

DISCLOSURES

MR: nothing to disclose; CYC: consulting for Roche, Janssen, MSD, Gilead, AstraZeneca, Lilly, TG Therapeutics, BeiGene, Novartis, BMS; research funding from BMS, Roche, AbbVie, honoraria from Roche, Janssen, MSD, Gilead, AstraZeneca, Eli Lilly, TG Therapeutics, BeiGene, Novartis, BMS; advisory board for Roche, Janssen, MSD, Gilead, AstraZeneca, Lilly, TG Therapeutics, BeiGene, Novartis, BMS; CEI: honoraria from Janssen, AbbVie, BeiGene, Lion Oncology, AstraZeneca; research funding from AbbVie, Janssen, BeiGene, ML: travel expenses from Celgene; education support from Janssen; PB: honoraria from AbbVie, Arrowhead, MSD; research funding from BeiGene, Roche; advisory board for EpiA Pharma, Janssen, MA: honoraria from Gilead, CSL, Novartis, Takeda, Janssen, AbbVie, AstraZeneca; employee of the Walter and Eliza Hall Institute; JM: VE: employee of and owns stock in BeiGene; SD: consulting for AbbVie, Antagonist, AstraZeneca, BeiGene, BMS, CSL, Behring, Gilead, Merck, Novartis, Janssen, Roche, Takeda; research funding from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmaceuticals, Roche, Takeda; honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Roche, Takeda; advisory board for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Roche, Takeda.

ACKNOWLEDGMENTS

We would like to thank the investigators, site support staff, and especially the patients for participating in this study. This study was sponsored by BeiGene. Editorial support was provided by Medical Expressions and funded by BeiGene.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from BSH and the authors of this poster.

